Karuna Therapeutics, Inc.
Karuna Therapeutics, Inc. (KRTX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
krtx · stock forecast · 25 analysts (3M) · FMP · updated Mar 9, 2025
Analyst Rating & Consensus
Based on 25 Wall Street analysts in the past 3 months
Buy
25 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$330
Consensus
$258
-21.9% upside
Low
$150
Median: $272.5 · Last Close: $329.83
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$257.50
-21.9% upside
High Target
$330
0.1%
Low Target
$150
-54.5%
Current Price
$329.83
as of today
Based on analyst price targets, the KRTX stock price prediction for the next 12 months ranges from $150 to $330. The consensus KRTX price forecast of $257.50 implies -21.9% upside from the current price of $329.83.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $333.43 | ↑ 1.09% |
1-day model range: $333.02–$333.84. Peak: $333.84 (+1.09%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · KRTX · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-03-14 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2024-03-11 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2024-02-20 | Cantor Fitzgerald | Maintains | Neutral→Neutral |
| 2024-01-26 | Mizuho | Downgrade ↓ | Buy→Neutral |
| 2024-01-17 | Cantor Fitzgerald | Maintains | Neutral→Neutral |
| 2023-12-28 | JP Morgan | Downgrade ↓ | Overweight→Neutral |
| 2023-12-26 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2023-12-22 | Morgan Stanley | Downgrade ↓ | Overweight→Equal Weight |
| 2023-12-22 | Wedbush | Downgrade ↓ | Outperform→Neutral |
| 2023-12-22 | Guggenheim | Downgrade ↓ | Buy→Neutral |
Wall Street analysts have recently issued updated ratings on Karuna Therapeutics, Inc. (KRTX) stock. Of the recent 138 rating actions, 0 were upgrades and 7 were downgrades. 25 analysts currently cover KRTX.
Analyst Recommendation Trends
KRTX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$57M
↓ 92.0% YoY
Revenue Next Year
$267M
↑ 371.2% YoY
EPS This Year
$-11.51
EPS Next Year
$-7.54
↓ 34.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast KRTX EPS of $-11.51 for the current fiscal year, based on estimates from 12 analysts. The KRTX revenue forecast is $57M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The KRTX stock forecast is supported by two independent data sources: analyst consensus ratings from 25 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus KRTX price target is $257.50 (-21.9% upside), with an analyst consensus of Buy.
The KRTX short-term stock prediction for tomorrow is $333.43 (+1.09%).
Karuna Therapeutics, Inc. trades on NASDAQ under the ticker KRTX. The KRTX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 64% of covering analysts.
Frequently asked questions
KRTX forecast · 8 questionsAccording to 25 Wall Street analysts, the average 12-month KRTX price target is $257.50, with a high forecast of $330.00 and a low of $150.00. The median price target is shown in the chart above when available. This implies -21.9% potential upside from the current price of $329.83.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.